News

Date
Title
Sort By:
03/31/26
SCYNEXIS Announces $40.0 Million Private Placement
03/31/26
SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
03/04/26
SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update
02/26/26
SCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247
01/28/26
SCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 Against Drug-Resistant Fungi, at the Inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI)
01/21/26
SCYNEXIS Receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations for SCY-247
12/22/25
SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
11/19/25
SCYNEXIS Completes Transfer of BREXAFEMME® New Drug Application to GSK
11/17/25
Scynexis Announces Federal Funding of Collaboration Between Hackensack Meridian CDI and Johns Hopkins Researchers to Develop New Therapeutics, Including Novel Fungerps, for Resistant Fungal Infections
11/05/25
SCYNEXIS Reports Third Quarter 2025 Financial Results and Provides Corporate Update